1.1K(top 0.1%)
papers
32.9K(top 1%)
citations
82(top 1%)
h-index
147(top 0.1%)
g-index
1.1K
all documents
35.6K
doc citations
3.6K
citing journals

Top Articles

#TitleJournalYearCitations
1Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trialLancet, The20171,749
2MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinibProceedings of the National Academy of Sciences of the United States of America20071,557
3B cells are associated with survival and immunotherapy response in sarcomaNature20201,158
4Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trialLancet Oncology, The2019767
5Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With SorafenibJAMA Oncology2020746
6Checkpoint Inhibitors in Metastatic EGFR- Mutated Non–Small Cell Lung Cancer—A Meta-AnalysisJournal of Thoracic Oncology2017653
7Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trialLancet Oncology, The2015574
8Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinomaJournal of Hepatology2022568
9Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studiesJournal of Hepatology2017465
10Management of gastric cancer in Asia: resource-stratified guidelinesLancet Oncology, The2013418
11Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysisBMJ: British Medical Journal2018362
12The VEGF-C/Flt-4 axis promotes invasion and metastasis of cancer cellsCancer Cell2006308
13CLINICAL STUDIES WITH CURCUMIN2007308
14Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b studyLancet Oncology, The2020300
15A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma: A randomized trialHepatology2008277
16SpecificEGFRMutations Predict Treatment Outcome of Stage IIIB/IV Patients With Chemotherapy-Naive Non–Small-Cell Lung Cancer Receiving First-Line Gefitinib MonotherapyJournal of Clinical Oncology2008249
17Chemotherapy-induced hepatitis B reactivation in lymphoma patients with resolved HBV infection: A prospective studyHepatology2014235
18Overview of current systemic management of EGFR-mutant NSCLCAnnals of Oncology2018229
19Translocation of Liposomes into Cancer Cells by Cell-Penetrating Peptides Penetratin and Tat: A Kinetic and Efficacy StudyMolecular Pharmacology2002228
20The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patientsOncotarget2016209
21Comparison of epidermal growth factor receptor mutations between primary and corresponding metastatic tumors in tyrosine kinase inhibitor-naive non-small-cell lung cancerAnnals of Oncology2009206
22136O: Osimertinib combined with durvalumab in EGFR-mutant non-small cell lung cancer: Results from the TATTON phase Ib trialJournal of Thoracic Oncology2016196
23Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall SurvivalJournal of the National Cancer Institute2017196
24CNS response to osimertinib in patients with T790M-positive advanced NSCLC: pooled data from two phase II trialsAnnals of Oncology2018193
2524-Month Overall Survival from KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin with or without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous Non–Small Cell Lung CancerJournal of Thoracic Oncology2019187
26Direct comparison of liposomal doxorubicin with or without polyethylene glycol coating in C-26 tumor-bearing mice: is surface coating with polyethylene glycol beneficial?Clinical Cancer Research1999186
27Treatment outcome and pattern of failure in 77 patients with sinonasal natural killer/T-cell or T-cell lymphomaCancer2004185
28Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinomaNature Medicine2022185
29IL-6 Trans-Signaling in Formation and Progression of Malignant Ascites in Ovarian CancerCancer Research2011184
30Afatinib for the Treatment of NSCLC Harboring Uncommon EGFR Mutations: A Database of 693 CasesJournal of Thoracic Oncology2020178
31Autophagy promotes resistance to photodynamic therapy-induced apoptosis selectively in colorectal cancer stem-like cellsAutophagy2014161
32Activating oxidative phosphorylation by a pyruvate dehydrogenase kinase inhibitor overcomes sorafenib resistance of hepatocellular carcinomaBritish Journal of Cancer2013160
33Early alpha‐fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinomaCancer2010154
34Osimertinib Plus Durvalumab versus Osimertinib Monotherapy in EGFR T790M–Positive NSCLC following Previous EGFR TKI Therapy: CAURAL Brief ReportJournal of Thoracic Oncology2019152
35Epidermal growth factor receptor mutations in needle biopsy/aspiration samples predict response to gefitinib therapy and survival of patients with advanced nonsmall cell lung cancerInternational Journal of Cancer2006151
36A multinational phase 2 study of nanoliposomal irinotecan sucrosofate (PEP02, MM-398) for patients with gemcitabine-refractory metastatic pancreatic cancerBritish Journal of Cancer2013146
37IMbrave150: Efficacy and safety results from a ph III study evaluating atezolizumab (atezo) + bevacizumab (bev) vs sorafenib (Sor) as first treatment (tx) for patients (pts) with unresectable hepatocellular carcinoma (HCC)Annals of Oncology2019146
38Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Non–Small-Cell Lung Cancer Patients with Leptomeningeal CarcinomatosisJournal of Thoracic Oncology2015145
39Radiotherapy in Lung Adenocarcinoma with Brain Metastases: Effects of Activating Epidermal Growth Factor Receptor Mutations on Clinical ResponseClinical Cancer Research2008140
40Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS–ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSOAnnals of Oncology2020138
41Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trialLancet Oncology, The2021136
42Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinomaBritish Journal of Cancer2010127
43The H3K9 methyltransferase G9a is a marker of aggressive ovarian cancer that promotes peritoneal metastasisMolecular Cancer2014127
44The STAT3-miRNA-92-Wnt Signaling Pathway Regulates Spheroid Formation and Malignant Progression in Ovarian CancerCancer Research2017127
45Orantinib versus placebo combined with transcatheter arterial chemoembolisation in patients with unresectable hepatocellular carcinoma (ORIENTAL): a randomised, double-blind, placebo-controlled, multicentre, phase 3 studyThe Lancet Gastroenterology and Hepatology2018127
46Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced, PD-L1–positive papillary or follicular thyroid cancerBMC Cancer2019126
47Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinomaJournal of Hepatology2010124
48Risk of Treatment-Related Toxicities from EGFR Tyrosine Kinase Inhibitors: A Meta-analysis of Clinical Trials of Gefitinib, Erlotinib, and Afatinib in Advanced EGFR -Mutated Non–Small Cell Lung CancerJournal of Thoracic Oncology2017122
49Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic studyLancet Respiratory Medicine,the2018121
50Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Second-Line Treatment of Patients With NSCLC: Results From an Expansion Cohort of a Phase 1 TrialJournal of Thoracic Oncology2020119